Published in Antimicrob Agents Chemother on October 01, 1998
Vancomycin-resistant enterococci. Clin Microbiol Rev (2000) 5.61
Antimicrobial susceptibility patterns of enterococci causing infections in Europe. The European VRE Study Group. Antimicrob Agents Chemother (1999) 1.35
Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. Infect Drug Resist (2015) 1.27
Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother (2003) 1.17
Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. Antimicrob Agents Chemother (2004) 1.10
Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob Agents Chemother (2008) 1.07
Broad Spectrum Antimicrobial Activity of Forest-Derived Soil Actinomycete, Nocardia sp. PB-52. Front Microbiol (2016) 0.82
Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother (2003) 0.79
Production of potent antimicrobial agent by actinomycete, Streptomyces sannanensis strain SU118 isolated from phoomdi in Loktak Lake of Manipur, India. BMC Microbiol (2014) 0.78
Pharmacokinetics of a new parenteral oligosaccharide antibiotic, SCH27899 (Ziracin), in healthy subjects. Antimicrob Agents Chemother (2001) 0.78
Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob Agents Chemother (2001) 0.77
Oritavancin diphosphate. Hosp Pharm (2014) 0.75
Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens. Ther Adv Infect Dis (2017) 0.75
Identification of Enterococcus species isolated from human infections by a conventional test scheme. J Clin Microbiol (1989) 13.84
Major trends in the microbial etiology of nosocomial infection. Am J Med (1991) 8.56
Emergence of Enterococcus as a significant pathogen. Clin Infect Dis (1992) 4.89
Nosocomial enterococci resistant to vancomycin--United States, 1989-1993. MMWR Morb Mortal Wkly Rep (1993) 4.77
Resistance to vancomycin and teicoplanin: an emerging clinical problem. Clin Microbiol Rev (1990) 3.82
Resistance of enterococci to glycopeptides. Antimicrob Agents Chemother (1990) 3.67
Current perspectives on glycopeptide resistance. Clin Microbiol Rev (1995) 2.99
Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group. Diagn Microbiol Infect Dis (1995) 2.87
In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. Antimicrob Agents Chemother (1996) 2.63
Cation components of Mueller-Hinton agar affecting testing of Pseudomonas aeruginosa susceptibility to gentamicin. Antimicrob Agents Chemother (1980) 2.01
The effect of cultural conditions on the activity of LY146032 against staphylococci and streptococci. J Antimicrob Chemother (1987) 1.89
Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics. Antimicrob Agents Chemother (1995) 1.86
Structure-activity relationships of vancomycin-type glycopeptide antibiotics. J Antibiot (Tokyo) (1993) 1.79
Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci. Antimicrob Agents Chemother (1996) 1.68
Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity. J Antibiot (Tokyo) (1996) 1.54
Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria. Antimicrob Agents Chemother (1995) 1.40
Influence of zinc on Pseudomonas aeruginosa susceptibilities to imipenem. J Clin Microbiol (1993) 1.28
In vitro activity and spectrum of LY333328, a novel glycopeptide derivative. Antimicrob Agents Chemother (1997) 1.27
In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide. Antimicrob Agents Chemother (1997) 1.19
Inhibition of peptidoglycan biosynthesis in vancomycin-susceptible and -resistant bacteria by a semisynthetic glycopeptide antibiotic. Antimicrob Agents Chemother (1996) 1.13
Factors influencing the vitek gram-positive susceptibility system's detection of vanB-encoded vancomycin resistance among enterococci. J Clin Microbiol (1996) 0.99
Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms. J Antimicrob Chemother (1997) 0.97
A critical appraisal of "chronic Lyme disease". N Engl J Med (2007) 7.84
Rapid assay for screening and characterizing microorganisms for the ability to degrade polychlorinated biphenyls. Appl Environ Microbiol (1986) 5.69
The objective evaluation of dysmenorrhea therapy. Am J Obstet Gynecol (1980) 4.38
Large lung bullae in marijuana smokers. Thorax (2000) 3.70
A multicenter clinical investigation employing ethinyl estradiol combined with dl-norgestrel as postcoital contraceptive agent. Fertil Steril (1982) 2.80
Transposition of plasmid DNA segments specifying hydrocarbon degradation and their expression in various microorganisms. Proc Natl Acad Sci U S A (1978) 2.55
Prevalence of faecal excretion of verocytotoxigenic Escherichia coli O157 in cattle in England and Wales. Vet Rec (2003) 2.22
Chromate resistance plasmid in Pseudomonas fluorescens. J Bacteriol (1983) 2.03
A precision measurement of the mass of the top quark. Nature (2004) 1.87
Identification of increased nitric oxide biosynthesis during pregnancy in rats. FASEB J (1993) 1.86
Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. N Engl J Med (1986) 1.76
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Endemic giardiasis in New Hampshire: a case-control study of environmental risks. J Infect Dis (1993) 1.60
Antibiotic-resistant isolates of Streptococcus pneumoniae from clinical specimens: a cluster of serotype 19A organisms in Brooklyn, New York. J Infect Dis (1986) 1.60
Selection for vancomycin resistance in clinical isolates of Staphylococcus haemolyticus. J Infect Dis (1990) 1.54
Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin, and rifampin used singly and in combination against Legionella pneumophila. Antimicrob Agents Chemother (1995) 1.52
Hemoglobin, methylene blue and oxygen interactions in human red cells. J Pharmacol Exp Ther (1972) 1.51
Risk factors for transmission of foot-and-mouth disease during an outbreak in southern England in 2007. Vet Rec (2011) 1.49
Diversity of Babesia infecting deer ticks (Ixodes dammini). Am J Trop Med Hyg (1998) 1.47
Faecal carriage of verocytotoxin-producing Escherichia coli O157 in cattle and sheep at slaughter in Great Britain. Vet Rec (2002) 1.46
Nitric oxide hemoglobin in patients receiving nitroglycerin as detected by electron paramagnetic resonance spectroscopy. J Lab Clin Med (1992) 1.45
Continuous low-level topical heat in the treatment of dysmenorrhea. Obstet Gynecol (2001) 1.43
Hydrogen sulfide poisoning. J Occup Med (1979) 1.43
Antibiotic optimization. An evaluation of patient safety and economic outcomes. Arch Intern Med (1997) 1.39
Medical preparation for travel in Africa. J Natl Med Assoc (1982) 1.39
Precipitation in Manchester: ketorolac/cyclizine. Anaesthesia (2001) 1.38
The effects of chemotactic factors on the adhesiveness of rabbit neutrophil granulocytes. Exp Cell Res (1979) 1.38
Tumor necrosis factor alpha has a protective role in a murine model of systemic candidiasis. Infect Immun (1994) 1.37
Current concepts about the treatment of selected poisonings: nitrite, cyanide, sulfide, barium, and quinidine. Annu Rev Pharmacol Toxicol (1976) 1.31
Participation of birds (Aves) in the emergence of Lyme disease in southern Maine. J Med Entomol (1998) 1.30
Susceptibility of Legionella pneumophila to eight antimicrobial agents including four macrolides under different assay conditions. J Antimicrob Chemother (1989) 1.30
Cloning of a Thiobacillus ferrooxidans plasmid in Escherichia coli. J Bacteriol (1984) 1.29
Biological approaches for polychlorinated biphenyl degradation. Basic Life Sci (1988) 1.29
Influence of zinc on Pseudomonas aeruginosa susceptibilities to imipenem. J Clin Microbiol (1993) 1.28
Nosocomial Mycobacterium fortuitum colonization from a contaminated ice machine. Am Rev Respir Dis (1988) 1.25
Susceptibility of Pseudomonas aeruginosa to serum bactericidal activity. A comparison of three methods with clinical correlations. J Lab Clin Med (1981) 1.24
Mycobacterium avium complex parotid lymphadenitis: successful therapy with clarithromycin and ethambutol. Pediatr Infect Dis J (1993) 1.23
Canine seroprevalence and the distribution of Ixodes dammini in an area of emerging Lyme disease. Am J Public Health (1991) 1.21
Management of acute sulfide poisoning. Effects of oxygen, thiosulfate, and nitrite. Arch Environ Health (1976) 1.20
DNA probes for the identification of Haemophilus ducreyi. J Clin Microbiol (1989) 1.19
The tolerance of coffee drinkers to caffeine. Clin Pharmacol Ther (1968) 1.18
Drug-induced methemoglobinemia. Semin Hematol (1973) 1.16
Pseudomonas aeruginosa: quantitation of maximum phagocytic and bactericidal capabilities of normal human granulocytes. J Lab Clin Med (1981) 1.15
Pseudomonas aeruginosa bacteremia: susceptibility of 100 blood culture isolates to seven antimicrobial agents and its clinical significance. J Lab Clin Med (1979) 1.15
In-vitro susceptibilities of Pseudomonas aeruginosa and Pseudomonas spp. to the new fluoroquinolones clinafloxacin and PD 131628 and nine other antimicrobial agents. J Antimicrob Chemother (1993) 1.15
Nitroprusside produces cyanide poisoning via reaction with hemoglobin. J Pharmacol Exp Ther (1974) 1.12
Comparative capacity of four antifungal agents to stimulate murine macrophages to produce tumour necrosis factor alpha: an effect that is attenuated by pentoxifylline, liposomal vesicles, and dexamethasone. J Antimicrob Chemother (1994) 1.10
Blue in the face. J Am Acad Dermatol (2001) 1.08
Vancomycin-resistant enterococci in stool specimens submitted for Clostridium difficile cytotoxin assay. Infect Control Hosp Epidemiol (1997) 1.07
Risk factors for endemic giardiasis. Am J Public Health (1987) 1.07
Post-coital contraception using d1-norgestrel/ethinyl estradiol combination. Contraception (1978) 1.05
The effect of ageing on the disposition of nifedipine and atenolol. Br J Clin Pharmacol (1988) 1.04
Epidemic Clostridium difficile-associated diarrhea: role of second- and third-generation cephalosporins. Infect Control Hosp Epidemiol (1994) 1.04
Assessing gravimetric estimation of intraoperative blood loss. J Gynecol Surg (1993) 1.04
The effect of methemoglobin on the inhibition of cytochrome c oxidase by cyanide, sulfide or azide. Biochem Pharmacol (1977) 1.02
Intestinal carriage of verocytotoxigenic Escherichia coli O157, Salmonella, thermophilic Campylobacter and Yersinia enterocolitica, in cattle, sheep and pigs at slaughter in Great Britain during 2003. Epidemiol Infect (2007) 1.01
Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. Thorax (1996) 0.99
Relation of induced tinnitus to physical characteristics of the inducing stimuli. J Acoust Soc Am (1967) 0.99
Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates. J Antimicrob Chemother (1986) 0.97
Transfusion-acquired babesiosis and failure of antibiotic treatment. JAMA (1986) 0.96
Comparative in-vitro susceptibilities of Pseudomonas aeruginosa, Xanthomonas maltophilia, and Pseudomonas spp. to sparfloxacin (CI-978, AT-4140, PD131501) and reference antimicrobial agents. J Antimicrob Chemother (1991) 0.96
Comparison of esophageal pressure with pulse transit time as a measure of respiratory effort for scoring obstructive nonapneic respiratory events. Am J Respir Crit Care Med (2000) 0.95
Factors related to the carriage of Verocytotoxigenic E. coli, Salmonella, thermophilic Campylobacter and Yersinia enterocolitica in cattle, sheep and pigs at slaughter. Epidemiol Infect (2009) 0.95
Trends in the therapy of acute poisonings. Clin Pharmacol Ther (1966) 0.95
Identification of a Haemophilus influenzae 5'-nucleotidase protein: cloning of the nucA gene and immunogenicity and characterization of the NucA protein. Infect Immun (2000) 0.95
Bioactivation of nitroprusside by porcine endothelial cells. Toxicol Appl Pharmacol (1994) 0.95
Competence of Peromyscus maniculatus (Rodentia: Cricetidae) as a reservoir host for Borrelia burgdorferi (Spirochaetares: Spirochaetaceae) in the wild. J Med Entomol (1993) 0.94
The effect of diabetes mellitus on chemotactic and bactericidal activity of human polymorphonuclear leukocytes. Diabetes Res Clin Pract (1987) 0.94
Necrotizing surgical infection and necrotizing fasciitis in obstetric and gynecologic patients. South Med J (1993) 0.94
Oropharyngeal and fecal carriage of Pseudomonas aeruginosa in hospital patients. J Clin Microbiol (1989) 0.93
Bacteremia in patients undergoing oral procedures. Study following parenteral antimicrobial prophylaxis as recommended by the American Heart Association, 1977. Arch Intern Med (1988) 0.93
A prevalence survey of infections in a combined acute and long-term care hospital. Infect Control (1984) 0.93
On the mechanism of sulfide inactivation by methemoglobin. Toxicol Appl Pharmacol (1966) 0.92
Enzootic Babesia microti in Maine. J Parasitol (2003) 0.92
Chemically induced methemoglobinemias in the mouse. Biochem Pharmacol (1967) 0.92
Severe reaction in domestic animals following the bite of Ixodes muris (Acari: Ixodidae). J Med Entomol (1999) 0.92
Interactions between hydroxocobalamin and nitric oxide (NO): evidence for a redox reaction between NO and reduced cobalamin and reversible NO binding to oxidized cobalamin. J Pharmacol Exp Ther (1995) 0.91
PRINCIPLE OF MINIMUM BENDING OF LOCALIZED AND DELOCALIZED ORBITALS; ETHANE BARRIER AND RELATED EFFECTS. Proc Natl Acad Sci U S A (1958) 0.91
First measurement of Bose-Einstein correlations in proton-proton collisions at √s=0.9 and 2.36 TeV at the LHC. Phys Rev Lett (2010) 0.91
In-vitro antimicrobial activity of enoxacin in combination with eight other antibiotics against Pseudomonas aeruginosa, Enterobacteriaceae and Staphylococcus aureus. J Antimicrob Chemother (1987) 0.91
Unrecognized association of sleep disorders and depression with chronic pelvic pain. South Med J (1992) 0.90
Probable strain differences of rats in susceptibilities and cardiopulmonary responses to chronic hypoxia. Respir Physiol (1983) 0.90
Concurrent chemotherapy and intensity-modulated radiation therapy for anal carcinoma--clinical outcomes in a large National Cancer Institute-designated integrated cancer centre network. Clin Oncol (R Coll Radiol) (2011) 0.89
Diurnal variation in response to thermal stimulation: mouse-hotplate test. Physiol Behav (1977) 0.88
A technic for the detection of rupture of the membranes. A review and preliminary report. Obstet Gynecol (1976) 0.88
Effects of cytokines and fluconazole on the activity of human monocytes against Candida albicans. Antimicrob Agents Chemother (2001) 0.88
In vitro activity of CI-934 and other antimicrobial agents against gram-positive and gram-negative bacteria. Clin Ther (1986) 0.88
The relationship among exercise, stress, and primary dysmenorrhea. J Behav Med (1989) 0.88
Genetic analysis of multiple vancomycin-resistant Enterococcus isolates obtained serially from two long-term-care patients. J Clin Microbiol (1998) 0.87
Photodynamic therapy for mesothelioma. Curr Treat Options Oncol (2001) 0.87